tarlatamab-dlle – BiotechReality – Information Intelligence System for Biopharma

Amgen has revealed ground-breaking findings from its Phase 3 DeLLphi-304 clinical trial, showing that Imdelltra® (tarlatamab-dlle) dramatically decreased the risk of death in patients with extensive-stage small cell lung cancer (ES-SCLC) by 40% when compared to standard chemotherapy. Patients whose illness had worsened after receiving platinum-based chemotherapy were included in the trial. The trial's primary aim was successfully met by Imdelltra, a first-in-class DLL3-targeting BiTE® molecule, which demonstrated a statistically significant and clinically relevant overall survival (OS) advantage over conventional chemotherapy. The median overall survival (OS) for patients in the Imdelltra group was 14.3 months, while that of patients in the chemotherapy arm was 9.6 months. Progress-free survival (PFS), the secondary goal, was also achieved, with the Imdelltra arm showing a notable improvement. Cytokine release syndrome (CRS) was the most often reported treatment-related adverse event, and the safety profile was in line with previous research. Early in the course of treatment, the majority of CRS patients were low grade. Small cell lung cancer is an extraordinarily aggressive and difficult-to-treat disease, and those living with SCLC often experience limited benefit with first line treatment, These data underscore IMDELLTRA's potential to transform patient outcomes and the small cell lung cancer treatment paradigm. Jay Bradner The data from DeLLphi-304 mark a major milestone for people with relapsed small cell lung cancer. Tarlatamab is associated with significant improvements in both overall and progression-free survival over standard chemotherapy in patients with recurrent or progressive disease, This study also provides confirmatory data on management of potential toxicities associated with bispecific T-cell engager therapies in a large patient cohort, which is crucial to continuing to improve the experience of patients treated with these medicines. Charles Rudin In a crucial trial for SCLC, Imdelltra—the first and only DLL3-targeting bispecific T-cell engager treatment with regulatory approval—showed an overall survival benefit. In May 2024, Imdelltra received accelerated approval from the U.S. Food and Drug Administration to treat adult patients with ES-SCLC whose disease has advanced during or following platinum-based chemotherapy. The goal of the DeLLphi-304 study is to facilitate a complete approval. Source: Amgen Last Modified:

Tag: tarlatamab-dlle

Amgen’s Imdelltra® (tarlatamab-dlle) Significantly Reduces Risk of Death by 40% in Small Cell Lung Cancer Phase 3 Trial

Areas Covered

Discover More

GSK Secures Japan Orphan Drug Designation for Risvutatug Rezetecan in Small-Cell Lung Cancer

Pfizer’s Talzenna + Xtandi Delivers Proven rPFS Breakthrough in HRR-Mutated mCSPC

Eli Lilly Declares Powerful 2% A1C Reduction and 17% Weight Loss in Landmark Phase 3 Trial Results of Retatrutide

ICOTYDE FDA Approval: J&J’s First-Line Oral Peptide Breakthrough for Plaque Psoriasis Treatment

Atirmociclib Phase 2 Breakthrough: Pfizer Declares Powerful Results for Metastatic Breast Cancer Treatment

EBGLYSS (lebrikizumab-lbkz) Delivers Remarkable Phase 3 Results for Pediatric Atopic Dermatitis Treatment